National Down Syndrome Society (NDSS) (original) (raw)

NDSS will be hosting an Externally-Led Patient Focused Drug Development (EL-PFDD) Meeting with the U.S. Food and Drug Administration (FDA) at 10 AM ET on June 2, to discuss Down Syndrome-associated Alzheimer's Disease (DS-AD).

The EL-PFDD meeting will give the FDA and other key decision makers the opportunity to hear directly from patients, their families, caregivers, and patient advocates specifically about the symptoms of DS-AD, the impacts on daily lives, patient experiences with current available treatments, and hopes for future therapies.